This page contains exclusive content for the member of the following sections: TTS, ITA. Log in to view.
Presenter: Jianing, Fu, New York, United States
Authors: Jianing Fu, Julien Zuber, Brittnay Shonts, Aleksandar Obradovic, Sai-Ping Lau, Thomas Savage, Amy Xia, Michael Simpson, Suxiao Yang, Michelle Miron, Yufeng Shen, Donna Farber, Mercedes Martinez, Adam Griesemer, Tomoaki Kato, Megan Sykes
Jianing Fu1, Julien Zuber1, Brittnay Shonts1, Aleksandar Obradovic1, Sai-Ping Lau1, Thomas Savage1, Amy Xia1, Michael Simpson1, Suxiao Yang1, Michelle Miron1, Yufeng Shen2, Donna Farber1, Mercedes Martinez3, Adam Griesemer1,4, Tomoaki Kato4, Megan Sykes1.
1Columbia Center for Translational Immunology, Department of Medicine, Columbia University, New York, NY, United States; 2Department of Systems Biology, Columbia University, New York, NY, United States; 3Department of Pediatrics, Columbia University, New York, NY, United States; 4Department of Surgery, Columbia University, New York, NY, United States
Donor T cell macrochimerism (>4%) often appears in blood without graft-versus-host disease (GVHD) following intestinal transplantation (ITx), and is associated with less graft rejection and donor-specific antibody (DSA) production[1][2]. Blood chimerism is also observed in other lymphoid and myeloid lineages[1]. We investigated the mechanisms underlying multilineage chimerism in blood.
We analyzed the repertoire, phenotype and origin of graft-resident and circulating donor T cells in ITx recipients using flow cytometry, mixed lymphocyte reaction and high-throughput TCR sequencing to identify and track alloreactive T cells.
Expanded graft-versus-host (GvH) clones triggered by rapidly replaced recipient antigen-presenting cells were detected early in intestinal biopsies (Figure 1A). Enrichment of graft GvH clones and absence of Class I DSA in the circulation were associated with donor T cell macrochimerism. The cumulative frequency of GvH clones in blood early post-Tx was correlated with peak donor T cell chimerism levels (Figure 1B). Frequencies of host-versus-graft (HvG) clones subsequently declined in the blood of a patient with a high level of T cell chimerism (>38%), suggesting that a lymphohematopoietic GvH response (without GVHD) may attenuate HvG responses (Figure 1C). While donor ileum lymphocytes display a tissue-resident memory (Trm) phenotype, circulating donor T cells include naïve and other non-Trm phenotypes (Figure 2A-B). Long-term circulating donor T cells were markedly enriched for the recent thymic emigrant phenotype and for T-cell receptor excision circles (TRECs) compared with recipient cells, suggesting they were recent thymic emigrants (Figure 2C-D). Donor circulating B cells and γδ T cells were also enriched for naïve phenotype compared to recipient cells. Myeloid lineage chimerism recurred at low levels late post-Tx in patients with macrochimerism. Consistent with the possibility that blood chimerism originated from progenitors in the graft, we detected donor-derived hematopoietic stem cells (HSCs) and/or hematopoietic progenitors (HPs) in human intestinal mucosa.
Our findings suggest that locally expanded GvH-reactive donor T cells in the graft enter the recipient circulation and attack host hematopoietic cells, which may allow the engraftment of graft-derived HSCs/HPs, thereby promoting sustained mixed chimerism. This pathway may help to reduce graft rejection and achieve tolerance after ITx.
Research reported in this publication was performed in the Columbia Center for Translational Immunology (CCTI) Flow Cytometry Core, supported in part by the Office of the Director, National Institutes of Health under awards S10RR027050 and S10OD020056. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. .
[1] Zuber J et al. Am J Transplant. 2015; 15: 2691–2703.
[2] Zuber J et al. Science Immunology. 2016; 1: eaah3732.
By viewing the material on this site you understand and accept that:
The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada